North American CRO, InterVivo Solutions, and UK/ Europe-based, Transpharmation, have come together as sister companies with a joint management team, following years of collaboration and joint ventures between the two.
Together, Transpharmation and InterVivo Solutions form the largest boutique Neuroscience-specialised small and large animal CRO, with 120 staff, a delivery footprint extending across North America, UK and Europe, consulting capability across Japan and Asia, and elevated capacity and opportunities for increased collaboration.
The merger will provide clients of each company with the strength of the other, opening new avenues for pre-clinical neuroscience projects with complementary assays, techniques and methodologies.
InterVivo Solutions CEO Joseph Araujo said: “The two leadership and delivery teams, now together as one, are a great fit. InterVivo started a joint venture with Transpharmation in 2017. We have operated collaboratively and extremely effectively as a boutique neuroscience company since then, with capabilities in PK, small molecule bio analysis and models across most CNS areas.”
Transpharmation CEO, Dr Mark Duxon, said: “We have had five years of joint working to really get to know each other, and this was the next natural step for our companies. This represents a significant growth strategy for us and for InterVivo Solutions. We will have a greater breadth of scientific resources available for drug developers and clients and a greater footprint across Europe, North America and Asia. We have brought together two really well established teams who are also leaders in their area.”
InterVivo Solutions and Transpharmation will strengthen their work on human neurodegenerative, pain and neuropsychiatric disorders, and continue to develop emerging research in novel pharmaceuticals and psychedelics for improving human health. In addition, the teams have world-leading technology platforms that include bioanalysis, EEG biomarker analysis, operant behaviour, imaging and automated assessment of spontaneous behaviour.
The merger has resulted in a combination of executive teams, with Transpharmation CEO, Dr. Mark Duxon, heading up the joint companies and InterVivo Solutions CSO, Dr. Guy Higgins, providing scientific leadership. Transpharmation CSO, Dr. Neil Upton, will move to a Scientific Advisory role across the group and Joseph Araujo, CEO of InterVivo Solutions, will move into a corporate development role and will continue to provide scientific leadership in expanding canine-based models.
All the laboratory and support teams across the companies’ laboratories will remain focussed on client work in their current labs but with greater ability for cross-company collaboration and expanded research capability in line with a combined growth strategy.
The move comes just a year after Transpharmation announced it was the very first company to co-locate alongside University of Warmia and Mazury in Olsztyn, Poland - and nine months after it expanded into new premises at Discovery Park in Kent, UK. Both InterVivo Solutions and Transpharmation have announced significant partnerships in the psychedelic space and remain at the forefront of this neuropsychiatric research.
Toronto, Ontario--(Newsfile Corp. - June 12, 2021) - InterVivo Solutions (IVS) today announced availability of its first data set as part of the COPETM program. The program, launched in March, in collaboration with Mindset Pharma Inc. (CSE: MSET) aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including Psilocybin, LSD, DMT, and 5-MeO-DMT amongst others.
Preliminary data released today focused on Psilocybin/Psilocin and demonstrate that the clinical exposure levels reported in humans correlate well to exposure and efficacy measures observed in mice - validating the predictive value of IVS's selected behavioural assays and animal models. Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to IVS' behavioral models.
As part of the COPETM program, IVS is immediately making available its Bioanalytical Platform to its global client base, offering pre-developed and qualified LC-MS analytical protocols for a growing list of known psychedelics and related chemical compounds, including their active metabolites. Sponsors will be able to submit their in-life samples for analysis at InterVivo's bioanalytical lab, centrally located in the Greater Toronto Area. Lead investigators for the platform are Drs. Inés de Lannoy and Lilia Magomedova, who are overseeing its development and application to profiling the pharmacokinetics properties of the selected psychedelic molecules.
"On this day, 78 years ago, the first woman in history experienced the effects of LSD. Susi Ramstein was a laboratory assistant with Albert Hoffman at Sandoz labs in Basel where LSD was first synthesised. Despite the widespread interest in the therapeutic potential of psychedelics, there is relatively little preclinical data relating their efficacy/safety profiles to plasma and CNS exposures, and PK properties. Developing this knowledge base for psychedelics such as LSD and psilocybin, currently being evaluated in the clinic, will undoubtedly help the value assessment of newer psychedelics in development. This requires significant expertise in bioanalysis and pharmacokinetics and we are fortunate to have the expertise and leadership of Drs. de Lannoy and Magomedova to lead this research." Dr. Guy Higgins, Ph.D., Chief Scientific Officer of IVS and a Scientific Advisory Board member of Mindset, commented.
James Lanthier, CEO of Mindset commented: "We are developing the tools and metrics with which the industry will determine success and we're doing it faster than anyone thanks to the expertise at InterVivo. We're delighted with the progress and insights driving the efficiency of our drug development engine, and are eager to translate that knowledge into real value for the mental health crisis we aim to solve. Given the significance of the date, today we also acknowledge the contributions of our research partners and in particular the many Women of Science who have made so many unsung contributions to humanity's understanding of nature and medicine.
Detailed information on the COPETM Benchmark data set and the Bioanalytical Platform is being made available immediately to IVS sponsors, and plans for public dissemination are forthcoming. For enquiries and further information on the COPETM Program or Bioanalytical Platform please contact:
Director of Sales and Marketing
Toronto, Ontario, February 4, 2021 – InterVivo Solutions Inc. (“InterVivo” or the “Company”), a leading Canadian contract research organization providing preclinical in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has been issued an Institution-wide Research License from Health Canada under the Cannabis Act and Cannabis Regulations.
The Institution-wide Research License (IRL) enables InterVivo to conduct multiple studies across all departments at its research facility without the need to apply for study-specific research licenses. Essentially, InterVivo is now granted broad approval to research and develop all cannabis-based products across all of its translational drug discovery services. InterVivo’s clients will benefit with reduced costs, greater study flexibility and shorter turnaround times for their cannabis research & development projects. The IRL will also provide the opportunity to run comparative studies against gold standard cannabinoids such as THC and CBD, as well as interrogate how these classic cannabinoids affect the brain and body.
Joseph Araujo, CEO and Co-Founder of InterVivo commented, “The medicines of the future will ultimately be based on a better understanding of the medicines of the past. As we learn more about how natural cannabinoid molecules work, as well as their limitations as therapies for disease, the better equipped we will be to help our clients design safer and more cost-effective therapies for the growing list of difficult-to-treat neurological conditions. Combined with our in-house expertise in psychedelics research, InterVivo is now poised to help accelerate the next generation of neuroscience drug discovery.”
For more information, please contact:
Director of Sales and Marketing
Please join us at the Alzheimer's Assocation International Conference in Chicago from July 22nd - July 26th. You can find us at booth #431.
Join InterVivo at booth #3319 in the 2018 Society for Neuroscience Conference in San Diego (November 3rd – 7th, 2018).
Dr. Guy Higggins has been invited to speak at this year's 11th International Society for Serotonin Research Meeting to be held July 9-12 in the Arabella Hotel and Spa in Hermanus, South Africa. His talk is entitled: Novel therapeutic opportunities for anti-obesity 5-HT2C receptor agonists in psychostimulant abuse and nicotine dependence. It will be part of the symposia session on The 5-HT2C receptor at the interface of obesity and addiction to be held on July 12.
InterVivo will be exhibiting as part of the Ontario Pavilion at this year's Bio International Convention in Boston. Learn more about InterVivo's capabilities by stopping by Booth #635.
InterVivo and Transpharmation will be speaking at this year's Neuro4D Conference in Mainz, Germany to be held June 4 - 5, 2018. For a confidential discussion about how we can help your degenerative disease drug discovery program, please contact Joseph Araujo (416-677-6085) to set up a meeting during the conference.
InterVivo Solutions and Transpharmation Ltd. announced today a strategic joint venture to co-market and co-develop an expansive suite of translational research services that will assist global pharmaceutical and biotech industries develop novel therapeutics to treat diseases of the Central Nervous System.
Join InterVivo at booth #2935 in the 2017 Society for Neuroscience Conference in Washington, D.C. (November 11 – 15, 2017).
InterVivo Solutions will be attending the 11th International Veterinary Behavior Meeting in Samorin, Slovakia, from September 14th to 16th.
Come join Intervivo Solutions, Booth #208, at this year’s Alzheimer’s Association International Conference in London, England.
InterVivo Solutions will be attending An Educational Course on Translating Research into Drugs, taking place in San Diego from February 12-14.
Join InterVivo at booth #3714 in the 2016 Society for Neuroscience Conference in San Diego (November 12 – 16, 2016). To find out more about our work, you can also drop by our poster presentations at:
|November 14, 2016|
|3:00 PM||396.11 / E6 - Characterisation of two NMDA NR2B subunit (grin2b) antagonists across tests of impulsivity and attention|
|4:00 PM||414.04 / S10 - A longitudinal study of PINK1 and PARK7 KO rats|
|November 15, 2016|
|9:00 AM||524.26 / RR9 - Validation of a translational pain questionnaire assessing behavioral quality of life measures in a naturalistic canine model of osteoarthritic pain and urate-induced pain|
Joseph Araujo will be speaking on September 18th at this year's Discovery to Development Symposium V in Montreal. Contact us to learn more about the Aged Dog Model and other services provided by InterVivo.
Joseph Araujo is currently in New Jersey to participate in the 17th International Conference on Alzheimer’s Drug Discovery to be held in Jersey City, September 12 - 13, 2016. If you would like to learn more about how IVS can assist in your Alzheimer’s drug discovery program, please contact Joseph at 416-677-6085 to set up a confidential meeting.
Join InterVivo Solutions for the annual Alzheimer’s Association International Conference. This year, it is being held in the Metro Toronto Convention Centre in Toronto, Canada from July 22 – 28. Visit us at Booth #726.
Dr. Guy Higgins will be speaking at the upcoming ISSR “Serotonin in Seattle” meeting in Seattle from 24th – 27th July 2016. Come to learn more about InterVivo’s research and services.
Join InterVivo at the International Society for the Study of Xenobiotics 11th annual conference in Busan, Korea from June 12 – 16, 2016. Visit us at booth #64 to learn more about our capabilities.
Joseph Araujo is currently in Europe to participate in this year’s 1st European Drug Discovery for Neurodegeneration Conference to be held in Budapest, Hungary, May 15 – 17, 2016. If you would like to learn more about how IVS can assist in your drug discovery program, please contact Joseph at 416-677-6085 to set up a confidential meeting.
InterVivo is exhibiting at the 10th Annual Drug Discovery for Neurodegeneration Conference: An Educational Course on Translating Research into Drugs, presented by the Alzheimer’s Drug Discovery Foundation, on March 6-8, 2016 in Miami Beach, FL. To learn more about how InterVivo can help with your drug development program, please stop by or contact Joseph Araujo (416-677-6085).
Joseph Araujo will be in Orlando, Florida to attend the 2016 North American Veterinary Conference on January 16 – 20. If you would like to set up an appointment to have a confidential discussion about InterVivo’s services, please contact him at 416-677-6085.
Joseph Araujo will be speaking at this year’s International Veterinary Behavior Meeting in Brazil, to be held Nov 11 - 13. If you will be in the area and would like to learn more about Intervivo’s capabilities in preclinical research, please contact Joseph Araujo at 416-677-6085 to set up an appointment.
InterVivo will be exhibiting at the 20th North American ISSX Meeting in Orlando, Florida to be held October 18 – 22, 2015. Please visit us at Booth #512 to learn more about our capabilities.
InterVivo will be participating at the 2015 Society for Neuroscience Conference in Chicago, Illinois to be held October 17 – 21, 2015. Join us at Booth #1753 or at one of our posters (details below) to learn more about our capabilities.
Joseph Araujo will be speaking at the “Behind the Curtain of Canine and Feline Dementia: From Neuroscience Research to Treatment” Conference to be held in Kosice, Slovakia on Tuesday, October 6, 2015. Please contact us to learn more about InterVivo’s research capabilities.
Dr. Guy Higgins will be presenting two posters at the joint meeting of the European Brain and Behaviour Society and the European Behavioural Pharmacological Society to be held on September 12 – 15, 2015. To learn more about our recent work involving Impulsivity and/or the Ketogenic diet please visit Dr. Higgins on September 14 and 15 at the Gran Guardia Palace in Verona, Italy.
Join us at Booth 531 at the Walter E Washington Convention Centre in Washington, DC for the 2015 Alzheimer's Association International Conference.
InterVivo is sponsoring next year's Canine Conference to be held in Niagara-on-the-Lake, Canada from Monday, June 15 to Wednesday, June 17, 2015. Visit the conference web site for more information.
This year, InterVivo will again be participating in the Neurotech Investing and Partnering Conference to be held in San Francisco, April 7th and 8th. Contact us to learn more about investment and partnering opportunities.
Intervivo will be exhibiting at the 12th International Conference on Alzheimer's and Parkinson's Disease. The 2015 AD/PD conference will be held in Nice, France on March 18-22. To learn more about our Alzheimer's and Parkinson's models, visit us at Booth #9.
InterVivo will be exhibiting at the 9th Annual Drug Discovery For Neurodegeneration Conference to be held in San Diego, March 1 – 3. Contact us if you would like to learn more about our services.
InterVivo will be attending the 2015 North American Veterinary Community Conference to be held in Orlando, Florida on Jan. 17-21. If you will be attending the conference and would like to learn more about InterVivo's capabilities in Early Safety or Toxicology please contact Joseph Araujo at 416-677-6085 to set up an appointment.
InterVivo Solutions will be hosting this year's Cognitive and Neurobiological Aging in the Dog Conference as a satellite session to the Society for Neuroscience conference. Plan to attend to learn more about the Aged Dog Model. The focus of this year's conference will be on the aged dog as a natural model of Alzheimer's disease progression for the assessment of new therapeutic measures. Registration for the conference is now open! For more information visit the conference web site or contact us.
Visit Intervivo at Booth #928 at this year's Society for Neuroscience conference to be held November 15-19 in Washington, D.C.
InterVivo will be exhibiting at this year's International Society for the Study of Xenobiotics (ISSX) conference. Join Drs. Lee and de Lannoy at the 19th North American Regional ISSX Meeting and 29th JSSX Annual Meeting, to be held on Oct. 19-23 in San Francisco to learn more about how IVS services can help with your preclinical needs.
The new Pink1 and Park7 KO rats from SAGE® Labs model familial genetic susceptibility to Parkinson’s disease in human populations. Our Chief Scientific Officer, Dr. Guy Higgins, is longitudinally characterizing these models using a functional observation battery (FOB) adapted from the Irwin test battery. InterVivo has partnered with SAGE® Labs to offer services including the FOB, pharmacological tests and DMPK studies, using SAGE's next-generation animal models. Please contact us if you wish to receive more information.
Join InterVivo at the 15th International Conference on Alzheimer's Drug Discovery in Jersey City, New Jersey on September 8-9.
InterVivo is once again sponsoring and speaking at this year's Canine Conference to be held in Lincoln, United Kingdom on Friday, July 18. Joseph Araujo will be speaking on the use of Dogs as Models of Human Aging. For details about the conference please visit the conference website.
InterVivo Solutions will again be an exhibitor at this year's Alzheimer's Association International Conference to be held in Copenhagen July 12-17. To learn about translational Alzheimer’s models please drop by booth C1-140.
Joseph Araujo will be attending this year's 9th FENS Forum of Neuroscience to be held in Milan, Italy from July 5-9. If you will be in the area and would like to set up a meeting time with Joseph, please contact him at 416-677-6085.
Intervivo is sponsoring the New England Drug Metabolism Discussion Group summer symposium to be held June 11 in Massachusetts. Come by our booth to learn more about IVS services!
InterVivo Solutions will be exhibiting at this year's
Canadian Society for Pharmaceutical Sciences Conference to be held in Montreal, Canada on June 10 – 13. To learn more about InterVivo's service offerings, please stop by or phone Joseph Araujo at 416-677-6085 to set up a meeting.
Joseph Araujo (President, IVS) will be attending The Neurotech Investing & Partnering Conference 2014 to be held in Boston on April 23-24, 2014. To find out more about how you can partner with InterVivo, please contact Joseph at 416-677-6085.
Joseph Araujo and Alex El Warrak will be attending BioTransfer 2014 to be held in Toronto, Ontario on March 18. If you would like to set up an appointment to discuss your project with InterVivo Solutions, please contact Joseph or Alex.
InterVivo Solutions is participating in this Spring's New England Drug Metabolism Discussion Group. If you will be in Boston on Wednesday, March 12, and want to get a customized quote or to learn more about the services being offered by InterVivo Solutions, please contact Sal Lemus.
A special Issue of Biochemical Pharmacology titled Pharmacology in 21st Century Biomedical Research features a review paper on pharmacokinetics co-authored by InterVivo's own VP of Research and Development, Dr. Inés de Lannoy. This exemplifies InterVivo's ongoing commitment to advancing the science and quality of drug discovery services we offer.
Joseph Araujo will be attending the 8th Annual Drug Discovery for Neurodegeneration Conference in Miami, Florida to be held February 2-4, 2014. If you will be attending the conference or if you will be in the Miami area and would like to arrange a confidential discussion about how Intervivo can help with your drug discovery program, please contact Joseph at 416-677-7085.
With these affordable rates, sponsors can obtain rodent and non-rodent exposure data earlier, to help guide optimization decisions and quickly build value in their discovery programs.
PhoenixBio USA and InterVivo Solutions are pleased to announce their partnership to offer Drug Research Studies using the PXB-Mouse®- A Chimeric Species of Mouse with a Humanized Liver.
InterVivo is pleased to announce that Alexander O. El-Warrak DMV, MSc, PhD has joined the senior management team of InterVivo as Director of Biomedical Device Research. Applying his extensive knowledge and expertise in animal surgery, Alex's primary goal will be to create a translational research pipeline for preclinical evaluation of safety and effectiveness of new medical devices and biomaterial solutions with an emphasis on those targeting age-related diseases. This effectively expands InterVivo's services to enable the evaluation of medical devices and combination drug products, as well as biomaterials and highlights InterVivo's commitment to offering innovative translational research solutions.
InterVivo Solutions will be exhibiting again at this year's Society for Neuroscience Conference in San Diego.
To learn more about our services offerings please stop by our booth #3329. To find out more about our latest findings visit us at one or all four of our posters (information below):
SAGE Labs Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, and InterVivo Solutions Inc., a leading provider of translational research services to improve clinical success of new drugs, jointly announced their partnership where SAGE Labs produces genetically engineered and validated animal models and InterVivo provides in-life and bioanalytical services.
As reported in Business Wire, InterVivo Solutions has joined with C2N Diagnostics and inviCRO in the formation of a novel and innovative Alzheimer's Disease research consortium. To learn more about this initiative and opportunities for working with the Consortium during 2013 and beyond, please contact either Joseph Araujo or our partners at C2N Diagnostics or inviCRO.
Please see the press release for more information.
InterVivo will be participating at this year's International Veterinary Behavior Meeting to be held in Lisbon, Portugal on September 26-29. Come and learn more about our imaging capabilities! Joseph Araujo will be on speaking on Thursday, September 26 on the Development and Application of a Brain Atlas for Evaluation of Canine Cognitive Decline Using PET-MR Techniques: Implication for Early Diagnosis of Cognitive Dysfunction Syndrome. For more information on the uses of the Aged Dog Model, please contact Joseph at 416-677-6085.
InterVivo Solutions is sponsoring this fall's New England Drug Metabolism Discussion Group. If you will be in Cambridge on Wednesday, September 11, stop by our booth to get a customized quote or to learn more about the services being offered by InterVivo Solutions.
Dr. Guy Higgins will be speaking at this year's EBPS meeting to be held from Sept. 6 - 9 in La Rochelle, France. His talk entitled, Serotonin, satiety and reward, will be given on Saturday, Sept. 7. Please drop by if you are in the area. For more information on our rodent models, you may speak with Guy directly at 416-716-5504.
InterVivo Solutions will be exhibiting again at this year's Alzheimer's Association International Conference to be held in Boston from July 13-18. Come visit us at Booth #1012 to learn more about our newly expanded set of services. Joseph Araujo will also be presenting our latest findings on the dog model of Alzheimer's Disease Progression on Wednesday, July 17 (11:45 am - 2:15 pm). Stop by our poster to learn more!
Joseph Araujo has been invited to attend this year's 4th Annual Biotechnology and Human Health Symposium in Prince Edward Island to be held on July 7-9. If you will be attending and want to learn more about partnering opportunities with InterVivo Solutions, please contact Joseph at 416-677-6085. If you are not attending the conference but you will be in the area and would like to meet with us, please feel free to contact us to arrange a meeting time.
Dr. Howard Dobson will be speaking at this year's 6th Imaging in Drug Discovery and Development Conference, on May 8-10, 2013 in Boston, MA. His talk, New developments in imaging biomarkers for the natural dog model of Alzheimer's Disease, will be given on May 9 at 4:20 pm.
Joseph Araujo will be participating at this year's Neurotech Investing and Partnering Conference at the St. Regis San Francisco on May 23-24, 2013. To learn more how you can partner with IVS, please contact Joseph at 416-677-6085.
InterVivo Solutions will be attending Neuroscience 2011 from November 12-16 in Washington, D.C. Please come visit us at booth 505.
InterVivo will be exhibiting at this year's Society for Neuroscience Conference. Visit us at Booth 2420 to learn more about our services and models.
Dr. Higgins will be presenting a poster at this year's World Pain Congress in Milan. Stop by his poster on Tuesday, August 28 between 9:45-10:45 am to learn more about the Pain Models being offered by InterVivo.
InterVivo will be exhibiting at the Alzheimer's Association International Conference in Vancouver, British Columbia.
Please visit us at booth #615 for a confidential discussion of how we can meet your needs.
InterVivo Solutions will be hosting a learning symposium at the NEOMED Institute on Monday, June 9. Dr. Guy Higgins will be speaking on the Development of a platform to study NCE's therapeutic potential in pain and epilepsy and Mr. Joseph Araujo will be speaking about Progressive canine disease models: Implications for development of CNS therapeutics.
InterVivo's President and Chief Executive Officer, Joseph Araujo, has been invited by the Department of Foreign Affairs and International Trade (DFAIT) to speak at a neuroscience partnering trade mission to Europe. Joseph will discuss InterVivo's portfolio of neuroscience projects available for partnering with the attendees of these by-invitation-only meetings. The meetings take place in London and Paris between January 23rd and 27th, 2012 and will include key European companies, institutions and agencies with interest and capacity to partner with Canadian organizations.
InterVivo has been invited to participate in another BioPartnering Mission. Joseph Araujo will be presenting the latest updates on models and services being offered by InterVivo at this year's Biopartnering Mission FutureEurope to be held in Brussels, Belgium.
InterVivo Solutions will be participating at this year's Bio International Convention to be held at McCormick Place in Chicago, Illinois. If you will be in the area and want to learn more about our capabilities please contact Sal Lemus at 647-293-7990.
Joseph Araujo and Guy Higgins will be presenting in the sessions on Aging Processes and Behavioral Pain Assessment, respectively, at this year's conference. For more information about the conference, please visit the conference web site.
Joseph Araujo and Guy Higgins will be presenting posters at this year's World Pharma Congress. The Drug Discovery Summit on Successful Targeting of Alzheimer's Disease will be held on June 7 to 9 in the Sheraton Philadelphia City Center in Philadelphia, Pennsylvania. If you will be in the area and would like to arrange to find out more about Intervivo Solutions' capabilities, please contact either Guy (416-716-5504) or Joseph (416-688-6085).